Rexahn Pharmaceuticals, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
  • Partnerships
  • Product Pipeline
    • Overview
    • RX-3117
    • RX-5902
    • RX-0301
    • Publications
  • Clinical Trials
    • Overview
    • Metastatic Pancreatic Cancer Clinical Trial
    • Advanced Bladder Cancer Clinical Trial
    • Triple Negative Breast Cancer Clinical Trial
    • Expanded Access Policy
  • News & Media
    • Press Releases
    • Presentations
    • Posters
    • Events
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact

Posters

News & Media

News & Media

  • Press Releases
  • Presentations
  • Posters
  • Events
Archexin, A Novel AKT-1 Specific Inhibitor for the Treatment of Metastatic Renal Cancer – Preliminary Stage 1 Data

Archexin, A Novel AKT-1 Specific Inhibitor for the Treatment of Metastatic Renal Cancer – Preliminary Stage 1 Data

Jan 7, 2016
New Data Demonstrate Supinoxin™ Dose Dependently Inhibits Tumor Cell Growth in a Preclinical Model of Triple Negative Breast Cancer

New Data Demonstrate Supinoxin™ Dose Dependently Inhibits Tumor Cell Growth in a Preclinical Model of Triple Negative Breast Cancer

Dec 8, 2015
RX-0201, An Anti-Sense Targeting AKT-1 to Treat Metastatic Renal Cancer – Preliminary Stage 1 Data

RX-0201, An Anti-Sense Targeting AKT-1 to Treat Metastatic Renal Cancer – Preliminary Stage 1 Data

Nov 6, 2015
Preliminary phase 1 data of single agent RX-3117, an oral antimetabolite nucleoside

Preliminary phase 1 data of single agent RX-3117, an oral antimetabolite nucleoside

Sep 25, 2015
Single Agent Supinoxin Targeting Phosphorylated p-68, Preliminary Phase I Data

Single Agent Supinoxin Targeting Phosphorylated p-68, Preliminary Phase I Data

Sep 25, 2015
A phase 1 exploratory study of RX-3117 to determine oral bioavailability in cancer subjects with solid tumors

A phase 1 exploratory study of RX-3117 to determine oral bioavailability in cancer subjects with solid tumors

May 29, 2015
A multicenter, open-label, proof of concept phase 1b/2 study to evaluate the safety and efficacy of RX-0201 in combination with everolimus to treat subjects with advanced renal cell carcinoma

A multicenter, open-label, proof of concept phase 1b/2 study to evaluate the safety and efficacy of RX-0201 in combination with everolimus to treat subjects with advanced renal cell carcinoma

May 29, 2015
A phase I study of RX-3117, an oral agent activated by uridine cytidine kinase 2, to treat subjects with advanced solid tumors

A phase I study of RX-3117, an oral agent activated by uridine cytidine kinase 2, to treat subjects with advanced solid tumors

May 29, 2015
A phase 1 study of RX-5902, an oral agent targeting phosphorylated p68, to treat subjects with advanced solid tumors

A phase 1 study of RX-5902, an oral agent targeting phosphorylated p68, to treat subjects with advanced solid tumors

May 29, 2015
Targeting localization and function of the RNA helicase DDX5/p68 With 1-(3,5-imethoxyphenyl)-4-[(6-fluoro-2-methoxyquinoxalin-3-yl) aminocarbonyl] piperazine (RX-5902)

Targeting localization and function of the RNA helicase DDX5/p68 With 1-(3,5-imethoxyphenyl)-4-[(6-fluoro-2-methoxyquinoxalin-3-yl) aminocarbonyl] piperazine (RX-5902)

Apr 18, 2015
RSS
  • « Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next »
Rexahn Pharmaceuticals, Inc.
© 2019 Rexahn Pharmaceuticals, Inc.
All Rights Reserved.
  • About
  • Overview
  • Management Team
  • Board of Directors
  • Contact
  • Privacy Policy
  • Disclaimer
  • Sitemap
  • Partnerships
  • Product Pipeline
  • Overview
  • RX-3117
  • RX-5902
  • RX-0301
  • Publications
  • Clinical Trials
  • Overview
  • Metastatic Pancreatic Cancer
  • Advanced Bladder Cancer
  • Triple Negative Breast Cancer
  • Expanded Access Policy
  • News & Media
  • Press Releases
  • Presentations
  • Posters
  • Events
  • Investors
  • Overview
  • News / Events
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
  • Corporate Governance
  • Contact
Privacy Policy Disclaimer Sitemap